Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

To the Editor: Solomon et al. (Oct. 24 issue) 1 report on the results of the PARAGON-HF (Prospective Comparison of ARNI [angiotensin receptor–neprilysin inhibitor] with ARB [angiotensin-receptor blockers] Global Outcomes in HF with Preserved Ejection Fraction) trial, which showed a lack of effect of sacubitril–valsartan in patients who had heart failure with preserved ejection fraction. The contrast of these results with those showing a benefit of sacubitril–valsartan in patients who have heart failure with reduced ejection fraction 2 has mainly been attributed to the heterogeneity of the population of patients who have heart failure with preserved ejection fraction. 3 We would like to . . .